Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Elsevier BV ; 1999
    In:  The Lancet Vol. 354, No. 9196 ( 1999-12), p. 2164-
    In: The Lancet, Elsevier BV, Vol. 354, No. 9196 ( 1999-12), p. 2164-
    Type of Medium: Online Resource
    ISSN: 0140-6736
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 1999
    detail.hit.zdb_id: 2067452-1
    detail.hit.zdb_id: 3306-6
    detail.hit.zdb_id: 1476593-7
    SSG: 5,21
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: PLOS ONE, Public Library of Science (PLoS), Vol. 12, No. 1 ( 2017-1-20), p. e0168601-
    Type of Medium: Online Resource
    ISSN: 1932-6203
    Language: English
    Publisher: Public Library of Science (PLoS)
    Publication Date: 2017
    detail.hit.zdb_id: 2267670-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 30, No. 11 ( 2021-11-01), p. 2030-2037
    Abstract: Postmenopausal pregnenolone and/or progesterone levels in relation to endometrial and ovarian cancer risks have been infrequently evaluated. To address this, we utilized a sensitive and reliable assay to quantify prediagnostic levels of seven markers related to endogenous hormone metabolism. Methods: Hormones were quantified in baseline serum collected from postmenopausal women in a cohort study nested within the Breast and Bone Follow-up to the Fracture Intervention Trial (B∼FIT). Women using exogenous hormones at baseline (1992–1993) were excluded. Incident endometrial (n = 65) and ovarian (n = 67) cancers were diagnosed during 12 follow-up years and compared with a subcohort of 345 women (no hysterectomy) and 413 women (no oophorectomy), respectively. Cox models with robust variance were used to estimate cancer risk. Results: Circulating progesterone levels were not associated with endometrial [tertile (T)3 vs. T1 HR (95% confidence interval): 1.87 (0.85–4.11); Ptrend = 0.17] or ovarian cancer risk [1.16 (0.58–2.33); 0.73] . Increasing levels of the progesterone-to-estradiol ratio were inversely associated with endometrial cancer risk [T3 vs. T1: 0.29 (0.09–0.95); 0.03]. Increasing levels of 17-hydroxypregnenolone were inversely associated with endometrial cancer risk [0.40 (0.18–0.91); 0.03] and positively associated with ovarian cancer risk [3.11 (1.39–6.93); 0.01]. Conclusions: Using sensitive and reliable assays, this study provides novel data that endogenous progesterone levels are not strongly associated with incident endometrial or ovarian cancer risks. 17-hydroxypregnenolone was positively associated with ovarian cancer and inversely associated with endometrial cancer. Impact: While our results require replication in large studies, they provide further support of the hormonal etiology of endometrial and ovarian cancers.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 16_Supplement ( 2020-08-15), p. 2359-2359
    Abstract: Progestogens are sex steroid hormones that serve as precursors to androgens, estrogens, and corticosteroids. While known to influence breast and endometrial cancer risk, the exact roles progestogens play in cancer development are poorly characterized–especially for colorectal cancer. Nor have we been able to determine the utility of measuring circulating progestogens for cancer risk prediction in epidemiologic studies and clinical settings. These gaps in knowledge are largely attributable to the difficulty in measuring hormones among postmenopausal women, when concentrations are low. To address this problem, we developed a highly sensitive and reliable liquid chromatography-tandem mass spectrometry assay to measure concentrations of seven markers of endogenous progestogen metabolism: pregnenolone (a progestogen precursor), progesterone, the two 17-alpha-hydroxy (17OH) forms of these hormones (which are androgen precursors), and three progesterone metabolites. These markers were measured in prediagnostic serum collected from women in a case-cohort study within the Breast and Bone Follow-up to the Fracture Intervention Trial (B~FIT). From the 15,595 postmenopausal women in B~FIT, we followed women not using exogenous hormones at baseline (1992-1993) for up to twelve years: 187 women with incident colorectal cancer diagnosed during follow-up and a subcohort of 495 women selected on strata of age (10-year windows) and clinical center. We used Cox regression models to estimate risk for colorectal cancer (hazard ratios [HR], 95% confidence intervals [CI] ); models were adjusted for age, body mass index, clinic site, and enrollment arm from the original clinical trial. High concentrations of progestogens were not associated with colorectal cancer risk (quintile(Q)5 vs. Q1: pregnenolone HR 0.71, CI 0.40-1.25; progesterone HR 1.25, CI 0.71, 2.22). A trend of increasing risk was suggested, but imprecise across quintiles of 17OH-pregnenolone (Q2 to Q5 HRs 0.75 to 1.44, p-trend 0.06), but no association was noted with 17OH-progesterone. Using 5-knot splines, we identified non-linear risk relationships with several of the progestogens–indicating that biologic mechanisms unique to each hormone may exist. However, circulating progestogens were generally unrelated to colorectal cancer risk in postmenopausal women, which is in line with prior work indicating that circulating estrogen metabolites are also not associated with risk. Citation Format: Kara A. Michels, Roni T. Falk, Ashley M. Geczik, Doug C. Bauer, Diana S. Buist, Jane A. Cauley, Cher M. Dallal, Trisha F. Hue, James V. Lacey, Andrea Z. LaCroix, Jeffrey A. Tice, Xia Xu, Louise A. Brinton, Britton Trabert. Endogenous progestogens and colorectal cancer risk among postmenopausal women [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2359.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: JAMA Internal Medicine, American Medical Association (AMA), Vol. 176, No. 1 ( 2016-01-01), p. 65-
    Type of Medium: Online Resource
    ISSN: 2168-6106
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2016
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Carcinogenesis, Oxford University Press (OUP), Vol. 35, No. 2 ( 2014-02-01), p. 346-355
    Type of Medium: Online Resource
    ISSN: 1460-2180 , 0143-3334
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2014
    detail.hit.zdb_id: 1474206-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 1603-1603
    Abstract: Background: A role for estrogen in colon carcinogenesis is suggested by the lower incidence of colorectal cancer (CRC) in women than men; the protective effect of exogenous hormones on risk; and reduced levels of estrogen receptor beta (ERβ) expression, the predominant ER in the colon, in cancerous compared to healthy colonic tissue. Nonetheless, the few cohort studies of endogenous hormones have not found reduced risks associated with circulating estradiol or estrone levels in postmenopausal women. We hypothesized that specific metabolites in the estrogen metabolic pathway may preferentially bind to and activate colonic ERβ, and analyzed a panel of 15 estrogen metabolites (EM), including estradiol and estrone, in a case-cohort study of CRC. Methods: We prospectively followed 15,595 women enrolled in B∼FIT (Breast and Bone Follow-up to the Fracture Intervention Trial (FIT)) who had completed questionnaires and donated blood between 1992 and 1993 for incident CRC through December 2004. Using liquid chromatography-tandem mass spectrometry, EM were measured in serum from 197 CRC cases and a subcohort of 491 women who were not using exogenous hormones at the time of blood draw. EM were examined individually, grouped by pathway (hydroxylation at the C-2, C-4, or C-16 positions of the steroid ring), and by ratios of the groupings. Cox proportional hazard regression models adjusted for clinical site and age (grouped in ten year intervals) were used to calculate quartile-specific hazard ratios (HRs) and 95% confidence intervals (CIs). Results: Significant risks were not observed for individual EM, and HR for quartiles of total EM (sum of all EM) were elevated but not significant (HRQ4 v Q1=1.23, 95% CI=0.8-2.0, ptrend=0.53). No associations were seen for estrone (HRQ4 v Q1=1.05, 95% CI=0.6-1.7) or estradiol (HRQ4 v Q1=0.90. 95% CI=0.5-1.5). When represented as a ratio to the parent estrogens (estrone and estradiol), risks of CRC for women with higher levels of 2-pathway EM or 4-pathway EM were reduced in each quartile, but neither HR nor trends were significant (ratio 2-pathway: parent, HRQ4 v Q1=0.88, 95 CI=0.6-1.4 ptrend=0.56; ratio 4-pathway: parent, HRQ4 v Q1=0.92, 95% CI=0.6, 1.5 ptrend=0.46). Conclusions: Levels of circulating estrone and estradiol and their metabolites are not associated with CRC risk in the B∼FIT cohort. Citation Format: Roni T. Falk, Cher M. Dallal, James V. Lacey, Douglas C. Bauer, Diana SM Buist, Jane A. Cauley, Trisha F. Hue, Andrea LaCroix, Jeffrey A. Tice, Ruth M. Pfeiffer, Xia Xu, Timothy D. Veenstra, Louise A. Brinton. Estrogen metabolites and colorectal cancer risk in postmenopausal women in the Breast and Bone Follow-up to the Fracture Intervention Trial (B∼FIT). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1603. doi:10.1158/1538-7445.AM2014-1603
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 940-940
    Abstract: Purpose: Mammographic breast density is an established and strong risk factor for breast cancer. Recently, a number of common genetic susceptibility loci have been identified as risk factors for breast cancer. We present the first report on the relative contribution of 76 validated breast cancer susceptibility loci, in the context of a polygenic risk score (PRS), to the breast density and breast cancer association. We also examine whether the PRS improves prediction of the Breast Cancer Surveillance Consortium (BCSC) 5-year risk model above and beyond breast density and clinical factors included in the model. Methods: The study population included 1643 cases and 2397 controls from three independent epidemiologic studies: the Mayo Mammography Health Study (MMHS), the Mayo Clinic Breast Cancer Study (MCBCS), and the Bavarian Breast Cancer Cases and Control Study (BBCC). Data collected on patients in each of the studies included clinical risk factor, BI-RADS breast density [a) almost entirely fat; b) scattered fibroglandular densities; c) heterogeneously dense; and d) extremely dense] and genotypes for the 76 breast cancer susceptibility loci known at the time of the study. We formed a PRS from the reported per-SNP odds ratios (OR) for 76 known breast cancer susceptibility loci, and evaluated whether BI-RADS density and the PRS were independent risk factors for breast cancer, when adjusted for age, 1/BMI and study. We also incorporated the PRS (OR) into the BCSC 5-year risk model and estimated 5-year risk for the MMHS nested case-control study of 339 invasive cases, 765 controls. Results: BI-RADS density (p & lt;0.0001) and PRS (p & lt;0.0001) were independent risk factors for breast cancer that together showed greater discrimination of risk (AUC=0.69) than density (AUC=0.66; ΔAUC=0.029) or PRS score alone (AUC=0.68; ΔAUC=0.013; p & lt;0.001). Relative to those with scattered fibroglandular densities and average (2nd quartile) PRS, women with extremely dense breasts and in the highest PRS quartile, had a 2.7 fold (95%CI: 1.7-4.1) increased risk of breast cancer, while those with fatty breasts and in the lowest PRS quartile had a reduced risk (OR=0.30, 95%CI: 0.18-0.51). Incorporation of the PRS into the BCSC risk model improved discrimination (ΔAUC=0.031, p=0.001), for a net reclassification improvement of 20% (95%CI: 11%-28%), split equally among cases (9%) and controls (11%). Conclusion: BI-RADS density and the PRS are both important risk factors for breast cancer that can be included in breast cancer risk models to improve prediction of this disease. Using these models to identify high and low-risk risk groups will facilitate improved tailored screening and primary prevention interventions. Citation Format: Celine M. Vachon, V. Shane Pankratz, Christopher G. Scott, Lothar Haeberle, Elad Ziv, Matthew R. Jensen, Kathleen R. Brandt, Dana H. Whaley, Janet E. Olson, Katharina Heusinger, Carolin C. Hack, Sebastian M. Jud, Matthias W. Beckmann, Jeffrey A. Tice, Kristen S. Purrington, Thomas A. Sellers, Karla Kerlikowske, Peter A. Fasching, Fergus J. Couch. The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 940. doi:10.1158/1538-7445.AM2014-940
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Cancer Prevention Research, American Association for Cancer Research (AACR), Vol. 5, No. 11_Supplement ( 2012-11-01), p. B86-B86
    Abstract: Background: While elevated circulating estrogens are consistently associated with increased postmenopausal breast cancer risk, less is known regarding the role of estrogen metabolism in breast carcinogenesis. Estrogen metabolism occurs via hydroxylation at the C-2,-4, or -16 positions, resulting in metabolites with potentially different genotoxic and mitogenic effects. To date, only two prior studies have examined comprehensive estrogen metabolism profiles in relation to postmenopausal breast cancer risk. Methods: We conducted a case-cohort study within B∼FIT (n=15,595), the Breast and Bone Follow-up to the Fracture Intervention Trial, to evaluate 15 pre-diagnostic serum estrogens and estrogen metabolites in relation to postmenopausal breast cancer risk. Participants included 387 breast cancer cases diagnosed during the 10-year follow-up and a subcohort of 492 women randomly selected from the cohort within 10-year age and geographical strata. At the screening visit (1992-1993), female volunteers ages 55-80 completed a baseline questionnaire and provided a blood sample. For cases, the average (SD) time between blood draw and diagnosis was 6 years (3.0). Serum concentrations of estrogens and estrogen metabolites were measured by liquid chromatography-tandem mass spectrometry. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard regression with robust variance adjustment. Exposures were categorized in quintiles (Q) based on the subcohort distribution; multivariable models were adjusted for study design variables (age, geographical site, and trial participation status). Known breast cancer risk factors were not included in the final models as additional adjustment did not alter the results. Estrogens were analyzed individually, as metabolic pathways (C-2, -4, or -16), and as ratios relative to the parent estrogens (estradiol and estrone). Results: Elevated circulating estradiol was significantly associated with increased breast cancer risk (HRQ5vsQ1=1.70; 95% CI: 1.08-2.69), although no dose-response was observed (p-trend=0.12). No significant associations were observed in the analysis of individual metabolites or the 2- and 4-hydroxylation pathways. However, women in the highest quintile of the 16-hydroxylation pathway were significantly more likely to develop breast cancer as compared to those in the lowest (HRQ5vsQ1=1.59; 95% CI: 1.02-2.48; p-trend=0.09). When analyzing each hydroxylation pathway relative to the parent estrogens, the ratio of the 2-hydroxylation pathway (HRQ5vsQ1=0.76; 95% CI: 0.50-1.17; p-trend=0.06), 4-hydroxylation pathway (HRQ5vsQ1=0.69; 95% CI: 0.45-1.06; p-trend=0.03) and 16-hydroxylation pathway (HRQ5vsQ1=0.72; 95% CI: 0.47-1.10; P-trend=0.29) to parent estrogens was suggestive of inverse associations. Additionally, a higher ratio of the 2- to 16-hydroxylation pathways was significantly associated with reduced risk (HRQ5vsQ1=0.66; 95% CI: 0.43-0.99; p-trend=0.009). Conclusions: Our results suggest that women with increased 2- or 4-hydroxylation, relative to their circulating parent estrogens, may be at lower risk of postmenopausal breast cancer. Analyses of metabolic pathways, in addition to individual metabolites, may help elucidate the role of estrogen metabolism in breast carcinogenesis. Citation Format: Cher M. Dallal, Jeffrey A. Tice, Diana S.M. Buist, Douglas C. Bauer, James V. Lacey, Jane A. Cauley, Trisha F. Hue, Andrea LaCroix, Roni Falk, Ruth Pfeiffer, Barbara J. Fuhrman, Timothy D. Veenstra, Xia Xu, Louise A. Brinton. Estrogen metabolism and postmenopausal breast cancer risk in the B∼FIT cohort. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B86.
    Type of Medium: Online Resource
    ISSN: 1940-6207 , 1940-6215
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2422346-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: npj Breast Cancer, Springer Science and Business Media LLC, Vol. 7, No. 1 ( 2021-08-03)
    Abstract: Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which high-risk women are likely to be using endocrine risk-reducing therapies among Athena Breast Health Network participants from 2011–2018. We identified high-risk women by a 5-year BCRAT risk ≥ 1.67% and those in the top 10% and 2.5% risk thresholds by age. We estimated the odds ratio (OR) of current medication use based on these thresholds using logistic regression. One thousand two hundred and one (1.2%) of 104,223 total participants used medication. Of the 33,082 participants with 5-year BCRAT risk ≥ 1.67%, 772 (2.3%) used medication. Of 2445 in the top 2.5% threshold, 209 (8.6%) used medication. Participants whose 5-year risk exceeded 1.67% were more likely to use medication than those whose risk was below this threshold, OR 3.94 (95% CI = 3.50–4.43). The top 2.5% was most strongly associated with medication usage, OR 9.50 (8.13–11.09) compared to the bottom 97.5%. Women exceeding a 5-year BCRAT ≥ 1.67% had modest medication use. We demonstrate that women in the top 2.5% have higher odds of medication use than those in the bottom 97.5% and compared to a risk of 1.67%. The top 2.5% threshold would more effectively target medication use and is being tested prospectively in a randomized control clinical trial.
    Type of Medium: Online Resource
    ISSN: 2374-4677
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2843288-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages